Sunitinib Malate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anaplastic Astrocytoma

Conditions

Anaplastic Astrocytoma, Glioblastoma

Trial Timeline

Mar 1, 2007 → Aug 1, 2012

NCT ID

NCT00606008

About Sunitinib Malate

Sunitinib Malate is a phase 2 stage product being developed by Pfizer for Anaplastic Astrocytoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00606008. Target conditions include Anaplastic Astrocytoma, Glioblastoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01073644	Pre-clinical	Terminated	Feb 1, 2010	Apr 1, 2010	Metastatic Renal Cell Carcinoma
NCT00912912	Phase 2	Terminated	May 1, 2009	Dec 1, 2014	Genitourinary Disease
NCT01118351	Phase 2	Terminated	Oct 1, 2008	Sep 1, 2015	Recurrent Bladder Cancer
NCT00753727	Phase 1/2	UNKNOWN	Sep 1, 2008	Mar 1, 2016	Soft Tissue Sarcoma
NCT00702884	Phase 2	Completed	Jun 30, 2008	Dec 30, 2013	Esophageal Cancer
NCT00716625	Pre-clinical	Completed	Jun 1, 2008	Oct 1, 2015	Carcinoma, Renal Cell
NCT00716820	Pre-clinical	Completed	Apr 1, 2008	Sep 1, 2016	Gastrointestinal Stromal Tumors
NCT00375674	Phase 3	Completed	Aug 1, 2007	Sep 7, 2017	Kidney Neoplasms
NCT00453310	Phase 2	Completed	Mar 1, 2007	Nov 1, 2008	Extragonadal Germ Cell Tumor
NCT00606008	Phase 2	Completed	Mar 1, 2007	Aug 1, 2012	Anaplastic Astrocytoma
NCT00465179	Phase 2	Completed	Mar 1, 2007	Mar 1, 2015	Renal Cell Cancer
NCT00434109	Phase 2	Completed	Nov 1, 2006	Feb 1, 2012	Neuroendocrine Tumor
NCT00495625	Phase 2	Terminated	Oct 1, 2006	Dec 1, 2010	Liver Cancer
NCT00397488	Phase 2	Completed	Sep 1, 2006	Feb 1, 2012	Bladder Cancer
NCT00338884	Phase 2	Completed	Sep 1, 2006	Apr 1, 2009	Carcinoma, Renal Cell
NCT00672594	Phase 2	Completed	Jul 1, 2006	Sep 1, 2013	Prostate Cancer

Competing Products

20 competing products in Anaplastic Astrocytoma

See all competitors

Product	Company	Stage	Hype Score
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	41
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	52
Lenvatinib 24 mg	Eisai	Phase 2	52
Lenvatinib + Nivolumab	Ono Pharmaceutical	Phase 2	52
durvalumab + tremelimumab	AstraZeneca	Phase 1	33
Pembrolizumab	Merck	Phase 2	52
LDK378 + AUY922	Novartis	Phase 1	33
ceritinib	Novartis	Pre-clinical	23
LDK378	Novartis	Phase 1	33
Ceritinib	Novartis	Phase 2	52
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim	Novartis	Phase 1	33
dabrafenib/trametinib	Novartis	Phase 2	52
Trametinib + Paclitaxel	Novartis	Phase 1	33
Alectinib + Crizotinib	Roche	Phase 3	77
Crizotinib (PF-02341066)	Pfizer	Phase 2	51
Lorlatinib	Pfizer	Phase 2	51
Crizotinib	Pfizer	Phase 1/2	40
Cemiplimab + XL092	Regeneron Pharmaceuticals	Phase 1	32
Etirinotecan pegol	Nektar Therapeutics	Phase 2	47
Bevacizumab	Novocure	Phase 2	47

Other Products from Pfizer